FMP
Regencell Bioscience Holdings Limited
RGC
NASDAQ
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
12.62 USD
-1.47 (-11.65%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Ebitda
-802.86k
-1.35M
-6.99M
-5.29M
-3.62M
-
-
-
-
-
Ebitda %
100
100
100
100
100
100
100
100
100
Ebit
-812.37k
-1.38M
-7.59M
-6.06M
-4.36M
-
-
-
-
-
Ebit %
100
100
100
100
100
100
100
100
100
Depreciation
9.52k
26.46k
604.4k
769.69k
745.59k
-
-
-
-
-
Depreciation %
100
100
100
100
100
100
100
100
100
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
386.98k
59.41k
16.42M
11.56M
7.96M
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
-
-
-
-
152.78k
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
-
-7.44k
-27.6k
-56.55k
-
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
-
-
-
-
-
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-117.84k
-
-780.88k
-27.39k
-5.38k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
Weighted Average Cost Of Capital
Price
12.62
Beta
Diluted Shares Outstanding
13.01M
Costof Debt
4.09
Tax Rate
After Tax Cost Of Debt
4.03
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
85.74k
Total Equity
164.22M
Total Capital
164.31M
Debt Weighting
0.05
Equity Weighting
99.95
Wacc
5.03
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Ebitda
-802.86k
-1.35M
-6.99M
-5.29M
-3.62M
-
-
-
-
-
Ebit
-812.37k
-1.38M
-7.59M
-6.06M
-4.36M
-
-
-
-
-
Tax Rate
1.41
1.41
1.41
1.41
1.41
1.41
1.41
1.41
1.41
1.41
Ebiat
-812.37k
-1.38M
-7.42M
-5.87M
-4.3M
-
-
-
-
-
Depreciation
9.52k
26.46k
604.4k
769.69k
745.59k
-
-
-
-
-
Receivables
-
-
-
-
152.78k
-
-
-
-
-
Inventories
-
-7.44k
-27.6k
-56.55k
-
-
-
-
-
-
Payable
-
-
-
-
-
-
-
-
-
-
Cap Ex
-117.84k
-
-780.88k
-27.39k
-5.38k
-
-
-
-
-
Ufcf
-920.69k
-1.35M
-7.58M
-5.1M
-3.77M
152.78k
-
-
-
-
Wacc
5.03
5.03
5.03
5.03
5.03
Pv Ufcf
145.46k
0
0
0
0
Sum Pv Ufcf
145.46k
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
5.03
Free Cash Flow T1
0
Terminal Value
0
Present Terminal Value
0
Intrinsic Value
Enterprise Value
145.46k
Net Debt
-2.88M
Equity Value
3.02M
Diluted Shares Outstanding
13.01M
Equity Value Per Share
0.23
Projected DCF
0.23215 -53.361%
